Research Article
Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer
Table 2
Association between tumor types and HPD for Immunotherapy-treated patients.
| | Tumor types | Non-HPD () | HPD () | The incidence of HPD | |
| | Lung cancer | 119 | 14 | 10.53% | | | Pancreatic cancer | 18 | 7 | 28.00% | | | Esophageal cancer | 8 | 2 | 20.00% | | | Colorectal cancer | 17 | 5 | 22.73% | | | Cholangiocarcinoma | 19 | 3 | 13.64% | | | Liver cancer | 15 | 2 | 11.76% | <0.01 | | Lymphoma | 25 | 1 | 3.85% | | | Ampullary carcinoma | 5 | 1 | 16.67% | | | Cervical carcinoma | 6 | 1 | 14.29% | | | Gastric carcinoma | 31 | 2 | 6.06% | | | Other | 76 | 0 | 0.00% | |
|
|
HPD: hyperprogressive disease.
|
